UroStream

At #EAU25, Dr. Vera R. and colleagues from Erasmus MC presented the first study to assess the environmental impact and staff requirements of radical cystectomy (RC) versus chemoradiation (CRT) for…

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…

Prostate biopsy remains the gold standard for diagnosing prostate cancer, but it carries risks such as infection, bleeding, and urinary obstruction. As a result, growing research interest has focused on developing “non-biopsy” diagnostic strategies. At the 2025 Annual Meeting of the European Association of Urology (EAU25), a study led by Professor Shouzhen Chen and Professor Benkang Shi from Qilu Hospital of Shandong University was selected for oral presentation. The study demonstrated that combining PSMA PET/CT, multiparametric MRI (PI-RADS score), and blood biomarkers—PHI and PSAD—can reduce the prostate cancer missed diagnosis rate to zero.

With diagnostic and therapeutic technologies advancing rapidly, precision treatment strategies for genitourinary malignancies such as urothelial carcinoma and prostate cancer are evolving with growing momentum. At the recent 2025 Annual Meeting of the European Association of Urology (EAU25), Professor Jeremy Teoh of The Chinese University of Hong Kong and Professor Yige Bao of West China Hospital, Sichuan University both presented major findings or received distinguished honors, showcasing the academic strength and international influence of Chinese urologists.  UroStream invited both experts for an insightful conversation on their research, clinical progress, and evolving strategies in the treatment of urothelial and prostate cancers.

The Phase 3 NIAGARA trial, presented at ASCO GU 2025, provides compelling evidence supporting perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC). The study highlights significant…

In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked the beginning of a new era in first-line treatment for advanced renal cancer. In 2024, several major breakthroughs were achieved. To provide deeper insights, Oncology Frontier invited Xinan Sheng, professor at Peking University Cancer Hospital, to summarize the key research developments that may serve as valuable references for future renal cancer treatment and research.

As 2024 concludes, the field of minimally invasive urological surgery has made remarkable strides, particularly in prostate cancer surgery, which often serves as a testing ground for innovative surgical approaches. With the advancement of precision medicine and multidisciplinary team (MDT) management, prostate cancer surgery now extends beyond simple tumor removal, incorporating preoperative diagnostic optimization, postoperative systemic therapy, and alternative local treatment approaches. In this annual review, Dr. Yao Zhu from Fudan University Shanghai Cancer Center summarizes the key developments in prostate cancer surgery over the past year.

Editorial Note: The ESMO Asia 2024 conference, hosted recently in Singapore, provided a platform for in-depth discussions on advancements in oncology. During the event, Urology Frontier had the opportunity to…